Overview

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Status:
Unknown status
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Liverpool
Collaborator:
AstraZeneca
Treatments:
Gemcitabine